ロード中...
The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a maj...
保存先:
| 出版年: | J Biomed Res |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Editorial Department of Journal of Biomedical Research
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5138586/ https://ncbi.nlm.nih.gov/pubmed/27924071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7555/JBR.30.20130172 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|